Global Blood Therapeutics Announces GBT440 Granted Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease

Global Blood Therapeutics Announces Upcoming Investor Webcast to Review GBT440 Data Being Presented at ASH that Support Sickle Cell Disease Program

Voyager Therapeutics and REGENXBIO Announce Exercise of Options for Rights to NAV Vectors

Warp Drive Bio Achieves Key Milestone in Antibiotics Collaboration with Sanofi

Blueprint Medicines Announces Proof-of-Concept Data from Global Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma